论文部分内容阅读
目的探讨肝细胞癌(hepatocellular carcinoma,HCC)术后复发的分子机理,同时寻找预测抑制术后复发的治疗药物。方法利用35例复发与41例未复发患者的基因表达谱数据,寻找术后复发相关差异表达基因,并进行基因本体(gene ontology,GO)与生物学通路(pathway)富集分析,寻找相关的生物学功能与通路,同时利用Connectivity Map(cmap)数据库区去预测可抑制HCC术后复发的潜在药物分子。结果发现HCC术后复发相关基因显著富集到了“黏着斑信号通路”、“MAPK信号通路”等相关通路中;同时发现了2个可能的潜在治疗药物“班布特罗”和“洛伐他汀”。结论 HCC术后复发相关基因涉及到“黏着斑信号通路”、“MAPK信号通路”等通路,且“班布特罗”以及“洛伐他汀”可能作为抑制HCC术后复发的潜在药物。
Objective To investigate the molecular mechanism of postoperative recurrence of hepatocellular carcinoma (HCC) and to search for the therapeutic drugs that predict the suppression of postoperative recurrence. Methods The gene expression profiling data of 35 patients with recurrent and 41 non-recurrent patients were used to search differentially expressed genes associated with postoperative recurrence. Gene ontology (GO) and biological pathway enrichment analysis were performed to search for relevant Biological functions and pathways, and use the Connectivity Map (cmap) database to predict potential drug molecules that can inhibit the recurrence of HCC. The results showed that the genes related to the recurrence of HCC were significantly enriched to related pathways such as “focal adhesion signal pathway” and “MAPK signaling pathway”. At the same time, two possible potential therapeutic agents were identified, including “bambuterol ”And“ lovastatin ”. Conclusion The relapse-related genes of HCC involve the pathways of “focal adhesion pathway” and “MAPK pathway”, and “bambuterol” and “lovastatin” may be used as inhibitors of HCC After the recurrence of potential drugs.